NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
 

SHOP APOTHEKE EUROPE starts the year strongly: Consolidated revenues increase by 33% to over EUR 174 million during the first quarter.

• DACH segment's revenues grow by +29% to EUR 154.9 million.
• International revenues rise by +81% to EUR 19.4 million.
• Number of active customers increases to 3.8 million.
• Forecast for the whole 2019 fiscal year confirmed.

Venlo, the Netherlands, 3 April 2019. SHOP APOTHEKE EUROPE N.V., Continental Europe's leading online pharmacy has started the 2019 fiscal year (January 1 - December 31) with substantial revenue increases, preliminary calculations show, with consolidated revenues growing by 33% to more than EUR 174 million during the first quarter of 2019 compared to EUR 130.7 million during the same period last year. The number of active customers rose by 41% year-on-year to 3.8 million. The Management Board confirms its forecast of an increase in revenues of around 30% to approximately EUR 700 million for the whole 2019 fiscal year.

SHOP APOTHEKE EUROPE grew dynamically in both its home and international markets. Revenues in the DACH segment (Germany, Austria and Switzerland) rose from EUR 120.0 million during the first quarter of 2018 to EUR 154.9 million - an increase of 29%.

The International segment, which covers business activities in France, Belgium, the Netherlands, Spain and Italy, posted revenues of EUR 19.4 million during the first quarter of 2019, up 81% compared to the same period a year when revenues were EUR 10.7 million.

The Management Board forecasts an acceleration of the company's organic growth to ca. 30% (2018: 25%) for the whole 2019 fiscal year, equivalent to an increase in revenues to around EUR 700 million (2018: EUR 540 million).

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the complete interim report for the first quarter 2019 as planned on May 15, 2019.

 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is the leading and fastest-growing online pharmacy in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership. The product range for the whole family in the OTC, beauty and personal care products as well as prescription drugs segments is supplemented by high quality natural food and health products, low carb products and sports nutrition following the acquisition of nu3 GmbH in July 2018.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain, the Netherlands and Switzerland.

SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to over 3.8 million active customers fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and on the SDAX since 24 September 2018

MEDIA CONTACTS.

Trade and popular media:
Sven Schirmer
Phone: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: presse@shop-apotheke.com

Investor relations:
Dr. Ulrich Wandel
Phone: +31 77 850 6117
Email: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This publication constitutes an advertisement. This announcement does not constitute an offer for sale or a solicitation of an offer to purchase securities of Shop Apotheke Europe N.V. in any jurisdiction. It does not constitute a securities prospectus. A public offer of securities of Shop Apotheke Europe N.V. is not taking place.

Statements contained herein could constitute so-called "forward-looking statements". Forward-looking statements can be recognized by words such as "might," "will," "should," "plans," "anticipates," "anticipates," "estimates," "believes," "intends," "aims," "aim" or their negative form or corresponding modifications and comparable terms.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, levels of utilization, developments and achievements of the Group or industry in which it operates to be materially different than those contained herein or implied. There should be no undue reliance on forward-looking statements. The Group will not update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.